Safety and efficacy of cilostazol in the management of intermittent claudication

Yung-wei Chi, Carl J. Lavie, Richard V. Milani, Christopher J. White

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Peripheral arterial disease (PAD) is a major health problem affecting millions of patients worldwide. Many will suffer from intermittent claudication (IC), which leads to marked impairment of quality of life (QoL). Besides surgical and endovascular interventions to improve limb-specific outcomes, pharmacotherapy is an effective tool in the treatment of IC. Cilostazol, a Federal Drug Administration-approved medication for the treatment of IC, has demonstrated consistent efficacy in improving exercise capacity and overall health-related QoL. This manuscript will review the pharmacokinetics, safety, and efficacy of cilostazol in the treatment of patients with IC as well as compare this agent with other proven non-invasive therapies for PAD.

Original languageEnglish (US)
Pages (from-to)1197-1203
Number of pages7
JournalVascular Health and Risk Management
Issue number6
StatePublished - 2008
Externally publishedYes


  • Cilostazol
  • Intermittent claudication
  • Peripheral arterial disease
  • Supervised exercise therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Hematology
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Safety and efficacy of cilostazol in the management of intermittent claudication'. Together they form a unique fingerprint.

Cite this